Multicell Technologies Inc (MCET)

Description:

MultiCell Technologies, Inc., a Delaware corporation was incorporated on April 28, 1970. It is a biopharmaceutical company developing novel therapeutics and discovery tools to address unmet medical needs for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology and peripheral vessel applications. The Company operates two subsidiaries, Xenogenics Corporation and MultiCell Immunotherapeutics, Inc. Its therapeutic development platform includes several patented techniques used to: (i) isolate, characterize and differentiate stem cells from human liver; (ii) control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as the Toll-like Receptors (TLRs), RIG-I-like receptor (RLR), and Melanoma Differentiation-Associated protein 5 (MDA-5) signaling; (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology; and (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway. The Company's portfolio of drug candidates in various stages of discovery optimization and preclinical and clinical development are: MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138-patient Phase IIa clinical trial; MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3, MCT-475, a discovery stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers. Many of the Company's competitors have greater financial, manufacturing, marketing and drug development resources than it does. It faces competition from pharmaceutical companies as well as biotechnology companies that are also researching and selling products similar to the Company. The research, testing, manufacturing, selling and marketing of drug candidates are subject to regulation by the FDA and other regulatory authorities in the United States and other countries, which regulations differ from country to country.